IDiyas

For the Inventor, By the Inventor

Nagoya, Japan

Yutaka Baba

USPTO Granted Patents = 11

Average Co-Inventor Count = 5.7

ph-index = 3

Forward Citations = 16(Granted Patents)


Location History:

  • Bisai, JA (1977)
  • Bisai, JP (1984)
  • Iwakura, JP (1988 - 1989)
  • Aichi, JP (1991 - 1995)
  • Nagoya, JP (1994 - 1996)

Company Filing History:

goldMedal11 out of 108 
 
Sanwa Kagaku Kenkyusho Co., Ltd.
 patents

Years Active: 1977-1996

Loading Chart...
11 patents (USPTO):Explore Patents
1. 5539125 - 1-azabicyclo[3.3.0]octan derivative, salt thereof, process for the (1996-07-23),
2. 5530138 - Compounds and use thereof (1996-06-25),
3. 5502209 - Benzopyrancarboxamide derivatives, salts thereof, process for the (1996-03-26),
4. 5442077 - Benzo[B]Furancarboxamide derivatives, process for the preparation of (1995-08-15),
5. 5434165 - Nootropic agents, compositions of, and method of use thereof (1995-07-18),
6. 5356880 - Glycyrrhetinic acid derivatives (1994-10-18),
7. 5008416 - Organogermanium compound, process for the preparation of same as well as (1991-04-16),
8. 4857521 - Trialkylsilyl pyridinium cephalosporin antibiotics (1989-08-15),
9. 4735943 - Eburnamonine oxime derivatives, salts thereof, and pharmaceutical agents (1988-04-05),
10. 4435392 - 2,5-Benzodiazocine derivatives and salts thereof, as well as (1984-03-06),
11. 4001249 - Process for the preparation of tropane alkaloids (1977-01-04),

Title: Yutaka Baba: Innovator in Pharmaceutical Chemistry

Introduction

Yutaka Baba is a prominent inventor based in Nagoya, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target neurological conditions. With a total of 11 patents to his name, Baba's work is recognized for its potential impact on treating diseases such as Alzheimer's.

Latest Patents

Among his latest patents is a 1-azabicyclo[3.3.0]octan derivative, which includes a pharmacologically acceptable salt of the compound. This compound is designed to act as a hypermotility agent. Additionally, he has developed another compound that binds with muscarinic receptors in the brain, which may serve as an effective ingredient for preventing and curing senile dementias, particularly Alzheimer's disease.

Career Highlights

Yutaka Baba is currently associated with Sanwa Kagaku Kenkyusho Co., Ltd., where he continues to innovate in the pharmaceutical sector. His research focuses on creating compounds that can significantly improve the quality of life for individuals suffering from neurodegenerative diseases.

Collaborations

Baba has collaborated with notable colleagues such as Kiichi Sawai and Masayasu Kurono, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Yutaka Baba's work exemplifies the intersection of innovation and healthcare, showcasing the importance of research in developing new treatments for debilitating conditions. His contributions to pharmaceutical chemistry are paving the way for advancements in the treatment of Alzheimer's disease and other neurological disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…